Company intelligence / Profile preview

Algok Bio

Bellevue, Washington, United Statesalgokbio.com ↗
Ownership
Private
Employees
~25
Development stage
Other
01

Overview

Idetrexed (Phase 1 completed, Phase 2 planned H2 2025); AGK-102 (preclinical, early clinical development in lung cancer planned 2024).

Therapeutic areas
Oncology
Modalities
Small moleculeMonoclonal antibody
Industry
Biotech
02

Drug pipeline

2 assets

CT900

1

1 more asset in the full pipeline.

03

Partnerships

BTG International Ltd.Institute of Cancer Research (ICR)

Beyond the preview

Go deeper on Algok Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Algok Bio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call